EW - Edwards releases real-world data on transcatheter aortic valve replacement

Real-world data shows that patients with bicuspid aortic stenosis treated with Edwards Lifesciences' (EW) SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement ("TAVR") had low risk of death and stroke one year following surgery.There were not significant differences in primary outcomes between bicuspid aortic patients and those with tricuspid aortic valve disease.A real-world registry analysis of 6,000 patients found that for patients treated with SAPIEN 3 TAVR at low surgical risk, all-cause mortality rate for bicuspid valves was similar at one year when compared to those with tricuspid valve disease (4.6% vs. 6.6%) as were stroke rates at one year (2.0% vs 2.1%).Edwards shares are unchanged in after-hours trading at $90.07.

For further details see:

Edwards releases real-world data on transcatheter aortic valve replacement